CR Double-Crane: Some drugs are proposed to be selected for national centralized drug procurement
CR Double-Crane announced that the company and some of its subsidiaries participated in the 11th batch of national centralized drug procurement, and some products are expected to be selected. The drugs expected to be selected include Metoclopramide Injection, Meprobamate Injection, Famotidine Injection, and Piracetam Oral Immediate Release Formulation. Among them, the expected selected price for Metoclopramide Injection is 0.68 yuan per vial, for Meprobamate Injection is 9.78 yuan per vial, for Famotidine Injection is 0.42 yuan per vial, and for Piracetam Oral Immediate Release Formulation is 7.87 yuan per bottle
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments